Literature DB >> 24900815

Synthesis and Anti-HCV Activity of 4-Hydroxyamino α-Pyranone Carboxamide Analogues.

Ananda Kumar Konreddy1, Massaki Toyama2, Wataru Ito2, Chandralata Bal1, Masanori Baba2, Ashoke Sharon1.   

Abstract

High genetic variability in hepatitis C virus (HCV), emergence of drug resistant viruses and side effects demand the requirement for development of new scaffolds to show an alternate mechanism. Herein, we report discovery of new scaffold I based on 4-hydroxyamino α-pyranone carboxamide as promising anti-HCV agents. A comprehensive structure-activity relationship (SAR) was explored with several newly synthesized compounds. In all promising compounds (17-19, 21-22, 24-25, and 49) with EC50 ranging 0.15 to 0.40 μM, the aryl group at C-6 position of α-pyranone were unsubstituted. In particular, 25 demonstrated potential anti-HCV activity with EC50 of 0.18 μM in cell based HCV replicon system with lower cytotoxicity (CC50 > 20 μM) and provided a new scaffold for anti-HCV drug development. Further investigations, including biochemical characterization, are yet to be performed to elucidate its possible mode of action.

Entities:  

Keywords:  Hepatitis C virus; non-nucleoside inhibitor; α-pyranone carboxamide

Year:  2013        PMID: 24900815      PMCID: PMC4027742          DOI: 10.1021/ml400432f

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  24 in total

Review 1.  Novel therapies for hepatitis C - one pill fits all?

Authors:  Michael P Manns; Thomas von Hahn
Journal:  Nat Rev Drug Discov       Date:  2013-06-28       Impact factor: 84.694

Review 2.  Current progress in development of hepatitis C virus vaccines.

Authors:  T Jake Liang
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 3.  Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses.

Authors:  Michael Houghton
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

4.  Potent and selective inhibition of hepatitis C virus replication by novel phenanthridinone derivatives.

Authors:  Mohammed T A Salim; Hiroshi Aoyama; Kazuyuki Sugita; Kouichi Watashi; Takaji Wakita; Takayuki Hamasaki; Mika Okamoto; Yasuo Urata; Yuichi Hashimoto; Masanori Baba
Journal:  Biochem Biophys Res Commun       Date:  2011-11-09       Impact factor: 3.575

5.  Diverse effects of cyclosporine on hepatitis C virus strain replication.

Authors:  Naoto Ishii; Koichi Watashi; Takayuki Hishiki; Kaku Goto; Daisuke Inoue; Makoto Hijikata; Takaji Wakita; Nobuyuki Kato; Kunitada Shimotohno
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 6.  Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.

Authors:  Michael J Sofia; Wonsuk Chang; Phillip A Furman; Ralph T Mosley; Bruce S Ross
Journal:  J Med Chem       Date:  2012-01-23       Impact factor: 7.446

Review 7.  The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.

Authors:  Ralf Bartenschlager; Volker Lohmann; Francois Penin
Journal:  Nat Rev Microbiol       Date:  2013-06-10       Impact factor: 60.633

8.  Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.

Authors:  Hui Li; John Tatlock; Angelica Linton; Javier Gonzalez; Tanya Jewell; Leena Patel; Sarah Ludlum; Matthew Drowns; Sadayappan V Rahavendran; Heather Skor; Robert Hunter; Stephanie T Shi; Koleen J Herlihy; Hans Parge; Michael Hickey; Xiu Yu; Fannie Chau; Jim Nonomiya; Cristina Lewis
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 8.039

9.  Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B.

Authors:  Ryan C Schoenfeld; David L Bourdet; Ken A Brameld; Elbert Chin; Javier de Vicente; Amy Fung; Seth F Harris; Eun K Lee; Sophie Le Pogam; Vincent Leveque; Jim Li; Alfred S-T Lui; Isabel Najera; Sonal Rajyaguru; Michael Sangi; Sandra Steiner; Francisco X Talamas; Joshua P Taygerly; Junping Zhao
Journal:  J Med Chem       Date:  2013-10-10       Impact factor: 7.446

10.  Exploratory study of oral combination antiviral therapy for hepatitis C.

Authors:  Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

View more
  2 in total

1.  Metal-Free Vinyl C-H Sulfenylation/Alkyl Thiolation of Ketene Dithioacetals for the Synthesis of Polythiolated Alkenes.

Authors:  Leiling Deng; Yunyun Liu
Journal:  ACS Omega       Date:  2018-09-25

2.  (2Z)-3-Hydroxy-3-(4-R-Phenyl)-Prop-2-Enedithioic Acids as New Antituberculosis Compounds.

Authors:  Gustavo Pretelín-Castillo; Mayra Silva Miranda; Clara Espitia; Rosa María Chávez-Santos; Abel Suárez-Castro; Luis Chacón-García; Rodrigo Aguayo-Ortiz; Roberto Martinez
Journal:  Infect Drug Resist       Date:  2021-10-20       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.